MannKind and Rose Pharma ink licensing deal for inhaled GLP-1
MannKind and Rose Pharma entered a licensing and collaboration agreement to develop an inhaled rapid-acting, short-duration GLP-1 for weight management.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.